Wachovia resumes coverage on Amgen (Nasdaq: AMGN) with an Outperform.

Wachovia analyst says, "Amgen's future growth hinges on denosumab, given ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE